Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Influenza A virus | Nonstructural protein 1 | Starlite/ChEMBL | No references |
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium tuberculosis | Hypothetical protein | Nonstructural protein 1 | 230 aa | 202 aa | 23.8 % |
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.3848 | 0.3848 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0021 | 0.0364 | 0.5 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0021 | 0.0364 | 0.0364 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0021 | 0.0364 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0021 | 0.0364 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0076 | 1 | 1 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0021 | 0.0364 | 0.0364 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0021 | 0.0364 | 0.5 |
Schistosoma mansoni | ap endonuclease | 0.0021 | 0.0364 | 0.0364 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.7163 | 0.7163 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0021 | 0.0364 | 0.5 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0021 | 0.0364 | 0.5 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0021 | 0.0364 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 1 | 1 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.3848 | 0.3848 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0021 | 0.0364 | 0.0364 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0021 | 0.0364 | 0.5 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.7163 | 0.7163 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 1 | 1 |
Toxoplasma gondii | exonuclease III APE | 0.0021 | 0.0364 | 0.5 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0021 | 0.0364 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.7163 | 0.7163 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 1 | 1 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0021 | 0.0364 | 0.0364 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0021 | 0.0364 | 0.0364 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0021 | 0.0364 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0021 | 0.0364 | 0.5 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0021 | 0.0364 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0021 | 0.0364 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.3848 | 0.3848 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.7163 | 0.7163 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0021 | 0.0364 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 2.6169 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 8.2753 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 11.2202 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 12.5893 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 21.3313 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Vif-A3F Interactions: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | 25.1189 uM | PubChem BioAssay. qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.